Ouro Medicines Secures $120 Million in Series A Funding to Revolutionize Treatment for Chronic Immune-Mediated Diseases

Ouro Medicines, a pioneering biotech company based in San Francisco, is thrilled to announce a remarkable funding round, successfully securing $120 million to advance its innovative research and development in immune reset therapeutics.

Focused on transforming the landscape of treatment for chronic immune-mediated diseases, Ouro Medicines leverages cutting-edge T cell engagers to specifically target B cell-mediated conditions.

This groundbreaking approach aims to induce immune resets, allowing patients to achieve long-term remission without the need for continuous immunosuppression, thereby significantly improving their quality of life.

Established through a collaborative effort between Monograph Capital and GSK, Ouro Medicines has garnered support from a robust consortium of leading investors, including TPG, NEA, and Norwest.

The newly raised funds will be instrumental in accelerating the company's clinical trials and expanding its therapeutic pipeline, with the ultimate goal of bringing new, safe, and effective therapies to patients in need.

As healthcare professionals increasingly seek innovative solutions to manage complex immune disorders, Ouro Medicines is positioning itself at the forefront of a paradigm shift in treatment options, underscoring its commitment to enhancing patient outcomes through science-driven advancements.

With the support of its talented team and strategic partners, Ouro is set to forge new pathways in immunology that promise to redefine the future of healthcare for countless individuals challenged by chronic diseases.